Angelini Pharma Presents Long-Term Data for cenobamate - Demonstrating Sustained Benefit in Adults Living with Epilepsy
Findings from a post-hoc analysis of the C017 open-label extension (OLE) study demonstrated sustained long-term reduction in seizure frequency with cenobamate, approved as adjunctive treatment in patients with focal onset seizures, after five years across eight different etiology categories